Cargando…

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

BACKGROUND: Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, is used worldwide in premenopausal women with hormone receptor-positive breast cancer. This study was conducted to assess the non-inferiority of the 6-month depot formulation, TAP-144-SR (6M) 22.5 mg to the 3-month dep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurebayashi, Junichi, Toyama, Tatsuya, Sumino, Shuuji, Miyajima, Eri, Fujimoto, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216102/ https://www.ncbi.nlm.nih.gov/pubmed/27017207 http://dx.doi.org/10.1007/s12282-016-0691-6

Ejemplares similares

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Kurebayashi, Junichi, et al.
Publicado: (2021)

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
por: Suzuki, Kazuhiro, et al.
Publicado: (2015)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
por: Kim, Dohee, et al.
Publicado: (2019)

Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008)

A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin
por: Park, Woo Sung, et al.
Publicado: (2014)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn, Ulf W, et al.
Publicado: (2013)

Leuprorelin/tamoxifen: Impairment of ventricular repolarisation reserve: case report
Publicado: (2021)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1990)

Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment
por: Muratori, L., et al.
Publicado: (2019)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot.
por: Matalliotakis, I M, et al.
Publicado: (2001)

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls
por: Yang, Kun, et al.
Publicado: (2021)

Foreign Body Granuloma Secondary to Leuprorelin Acetate
por: Lee, Bo In, et al.
Publicado: (2014)

Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer
por: Tan, Hsern Ern, et al.
Publicado: (2016)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate
por: Okada, Akie, et al.
Publicado: (2022)

Sex Hormone Dependency of Diethylnitrosamine‐induced Liver Tumors in Mice and Chemoprevention by Leuprorelin
por: Nakatani, Tamaki, et al.
Publicado: (2001)

Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study
por: Braeckman, Johan, et al.
Publicado: (2014)

Polymorphism in magic-sized Au(144)(SR)(60) clusters
por: Jensen, Kirsten M.Ø., et al.
Publicado: (2016)

Coherent vibrational dynamics of Au(144)(SR)(60) nanoclusters
por: Zhang, Wei, et al.
Publicado: (2022)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
por: Thorén, Linda, et al.
Publicado: (2020)

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women
por: Eriksson, Mikael, et al.
Publicado: (2021)

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
por: Saladores, P, et al.
Publicado: (2015)

Inactivation of the retinoblastoma tumour suppressor pathway in premenopausal breast cancer is associated with resistance to tamoxifen
por: Lehn, S, et al.
Publicado: (2009)

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
por: Lee, Maria, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate
por: Yamauchi, Ryo, et al.
Publicado: (2020)

Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
por: Saito, Seiichi
Publicado: (2019)

Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
por: Chung, Byung Ha, et al.
Publicado: (2020)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature
por: Benabbad, Imane, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4spi2l9e9bn3g5k0gd2mr4nk9i